A Proteogenomic Atlas of Clear Cell Renal Cell Carcinoma in a Chinese Population

Chen Ding,Yuan-Yuan Qu,Jinwen Feng,Xiaohui Wu,Lin Bai,Wenhao Xu,Lingli Zhu,Yang Liu,Fujiang Xu,Xuan Zhang,Guojian Yang,Jiacheng Lv,Xiuping Chen,Guohai Shi,Hongkai Wang,Dalong Cao,Hang Xiang,Lingling Li,Subei Tan,Hualei Gan,Menghong Sun,Hailiang Zhang,Jian-Yuan Zhao,Dingwei Ye

DOI: https://doi.org/10.21203/rs.3.rs-221123/v1

2021-01-01

Abstract:Abstract Renal cell carcinoma (RCC) is among the top 10 malignant carcinomas1. Clear cell (cc)RCC, accounting for ~ 75% of RCC cases, is an aggressive histological RCC subtype. In the last decade, large-scale multiomics studies have profoundly enhanced our understanding of this disease2,3. However, despite the differences of genomic alterations between Western and Eastern ccRCC4,5, these studies mostly focused on patients in Western populations. Here we conducted a comprehensive proteogenomic analysis of 232 tumor and adjacent non-tumor tissue pairs from Chinese ccRCC patients. Genomic analysis revealed unique genetic features of Chinese ccRCC and distinct mutation patterns associated with copy number alterations. Based on proteomic profiles, ccRCC showed extensive metabolic dysregulation, especially in one-carbon metabolism. We classified ccRCC into three subtypes (GP1–3), among which the most aggressive GP1 exhibited dominant immune response, metastasis, and metabolic imbalance, linking the proteomic features, genomic alterations, and clinical outcomes of ccRCC. Nicotinamide N-methyltransferase (NNMT) and NNMT mediated protein homocysteinylation were identified as a poor prognosis indicator and a drug target for GP1, respectively. We demonstrated that NNMT induces DNA-dependent protein kinase catalytic subunit (DNA-PKcs) homocysteinylation, increases DNA repair, and promotes tumor growth in ccRCC. Treatment of N-acetyl-cysteine (NAC), an inhibitor of homocysteinylation, markedly reduced the NNMT overexpression induced radioresistance of tumor cells. This study provided valuable insights into the biological underpinnings and prognosis assessment of ccRCC, revealing a targetable metabolic vulnerability.